The present invention relates the field of animal health. Particularly, the present invention relates to a recombinant classical swine fever virus E2 protein in which a fragment comprising at least one of the amino acids defining the 6B8 epitope of the CSFV E2 protein is replaced by a corresponding fragment of the E2 protein from a pestivirus other than CSFV. Further, the present invention provides an immunogenic composition comprising the recombinant E2 protein of the present invention and the use of the immunogenic composition for preventing and/or treating diseases associated with CSFV in an animal. Moreover, the present invention provides a method and a kit for differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

Provided are a recombinant classical swine fever virus comprising at least one substitution within the epitope of the E2 protein specifically recognized by the 6B8 monoclonal antibody, an immunogenic composition comprising said CSFV, the use of said immunogenic composition for preventing and/or treating diseases associated with CSFV in an animal, a method or a kit for differentiating animals infected with CSFV from animals vaccinated with said immunogenic composition, and an attenuated classical swine fever viruses.

The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

The present invention relates to the field of veterinary diagnostics, specifically to a test for the detection of antibodies against CSFV. In particular the invention relates to a method for detecting antibodies against wild type CSFV in a test sample, characterized in that the method comprises co-incubating with a carrier comprising a mutated TAVSPTTLR epitope of CSFV E2 protein. Further, the invention relates to a diagnostic test kit, and to the use of the method according to the invention. In addition the invention relates to a method for differentiating between animals infected with wild type CSFV and animals that were vaccinated against CSFV with a CSFV (marker) vaccine, and to a method for controlling an infection with wild type CSFV in a population of porcine animals, by the combined use of a CSFV (marker) vaccine and the diagnostic test kit of the invention.

Provided is a recombinant vector including a new BiP gene fragment, and when a target protein is prepared using the recombinant vector of the subject matter, use stability can be enhanced and the production amount of target protein can also be increased by minimizing a foreign peptide sequence remaining in the target protein.

Described herein are engineered fusion proteins comprising a variant protease (e.g., an HCV NS3 protease) fused to a polypeptide of interest and a cognate protease cleavage site. The cleavability of the cognate protease cleavage site enables the controllability of one or more functions of the polypeptide of interest. Additionally disclosed are methods for generating engineered fusion proteins as well as their therapeutic use.

The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.

The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

Provided is a recombinant vector including a new BiP gene fragment, and when a target protein is prepared using the recombinant vector of the subject matter, use stability can be enhanced and the production amount of target protein can also be increased by minimizing a foreign peptide sequence remaining in the target protein.

The invention relates to a Quadruple Gene Deleted Mutant Bovine Herpesvirus Type 1 (BHV-1 QMV) engineered to express protective antigens derived from viruses associated with infection in livestock. The recombinant vector includes a deletion of a cytoplasmic tail of envelope glycoprotein gE (gE-CT), a truncation of glycoprotein gG, a deletion of envelope protein UL49.5 amino acid residues 30-32, and a deletion of UL49.5 cytoplasmic tail amino acid residues 80-96. The truncation of glycoprotein gG comprises a deletion of amino-terminal amino acid residues 1-67. The recombinant vector can include at least two heterologous antigens inserted therein. Included are methods for creating recombinant vectors, mutant viruses, and vaccines for preventing or reducing symptoms associated with viral infection in livestock, in particular bovine respiratory viral infection